Eton Pharmaceuticals (ETON)
(Delayed Data from NSDQ)
$5.42 USD
-0.48 (-8.14%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.39 -0.03 (-0.55%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Brokerage Reports
Eton Pharmaceuticals, Inc. [ETON]
Reports for Purchase
Showing records 1 - 20 ( 37 total )
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Positive Operating Cash Flow Achieved; 3Q23 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line Beat; Profitability in Sight; Raising PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
DS-100 Receives Complete Response Letter; Lowering PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Top- and Bottom-Line 1Q23 Beat; Pipeline Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Revenue In Line, Bottom-Line Beat; 2022 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Dehydrated Alcohol Response Submitted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Betaine Anhydrous Acquisition Should Boost Sales; Raising PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Negative Cysteine HCl Patent Ruling Does Not Impact Our Thesis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Rare Disease Product Strategy Bearing Fruit; 2Q22 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Zonisamide Approval; Hospital-Based Portfolio Sold; Adjusting PT to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Cysteine Hydrochloride Receives FDA Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2021 Financial Results Reported; Lowering PT to $11
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Rezipres Launch Approaching; 2Q21 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Topiramate Approval Decision Delayed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Portfolio Updates; Looking Ahead to Revenue Ramp; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Product Portfolio Poised for Growth; 2020 Financials; Modulating PT to $14
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Regulatory Catalysts; Alkindi Sprinkle Canadian Rights Obtained; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Eton Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2021 Forecasts Revised, Notwithstanding Pipeline Advances; Lowering PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R